Time：2026-10-10
On
September 24, 2026, Medtide Inc. (HKEX: 3880, “Medtide” or the “Company”)
announced that it has completed the acquisition of an industrial land parcel
and the buildings on it in Qiantang District, Hangzhou. The site will be used
for Phase I of the Company’s large-scale CDMO manufacturing base (the
“Project”), marking a key step forward in the Company’s strategic capacity
expansion for its peptide and oligonucleotide CDMO business.
Phase
I: Bringing Large-Scale Peptide API Capacity Online
The
Project covers approximately 30 mu (20,000 square meters), with existing plant
facilities of approximately 13,500 square meters. The Company plans to build
large-scale peptide API production lines at the site, with a designed annual
capacity expected to be 3–5 metric tons, further strengthening its large-scale
manufacturing capabilities and its capacity to take on commercial projects.
Phase
II: Building a Large-Scale CDMO Manufacturing Site of Approximately 86 Mu
Building
on Phase I, the Company intends to integrate an adjacent parcel of
approximately 56 mu (37,000 square meters) in Phase II, creating a large-scale
CDMO manufacturing park with a total area of approximately 86 mu (57,000 square
meters). This will continue to expand capacity to meet large-scale
manufacturing demand and further enhance the Company’s ability to undertake
major commercial projects.
Strategic
Positioning: Seizing Opportunities in the Peptide and Oligonucleotide Industry
In
recent years, research and development of peptide and oligonucleotide drugs has
continued to accelerate, and as these therapies scale commercially, demand is
rising for large-scale, reliable supply of upstream APIs. This capacity
expansion is a key strategic move for the Company’s peptide and oligonucleotide
CDMO business and another solid step in its long-term commitment to this field.
The new large-scale manufacturing base is expected to enhance the Company’s
CDMO service and capacity, better meet the needs of global clients at every
stage from R&D to commercialization, and create long-term value for
shareholders.
Looking
Ahead
Medtide
will continue to advance the Project’s construction. Going forward, the Company
will continue to leverage its professional technology platforms and reliable
manufacturing capacity to provide efficient, dependable CDMO services to
innovative pharmaceutical partners worldwide, helping bring more innovative
medicines to patients sooner.
About
Medtide
The Company is a leading, publicly listed global Contract Research, Development, and Manufacturing Organization (CRDMO) that officially listed on the main board of the Hong Kong Stock Exchange in 2025. Strategically leveraging its vertically integrated platform, proprietary technology engines, and advanced manufacturing infrastructure across the United States and China, the Company is dedicated to accelerating the development and sustainable commercial supply of advanced peptide and oligonucleotide therapeutics worldwide.
Learn more at: www.medtideinc.com/
